Korelasi RDW (Red-Cell Distribution Width) dengan NT-PROBNP (N-TERMINAL PRO-BRAIN Natriuretic Peptide) pada Gagal Jantung Kronik yang Tidak Terkompensasi
DAFTAR PUSTAKA
1.
Francis GS, Gassler JP, Sonnenblick EH. Pathophysiology and Diagnosis of
Heart Failure. In: Fusler V, Alexander RW, O’Rourke RA (ed). The Heart
10th edition. 2005;1:655-685.
2.
Colucci WS. Nesiritide for the treatment of decompensated heart failure. J
Card Fail. 2001;7(1):92-100.
3.
Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated
into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of
Heart Failure in Adults A Report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines
Developed in Collaboration With the International Society for Heart and
Lung Transplantation. J Am Coll Cardiol. 2009;119:393-475.
4.
Levy D, Kenchaiah, Larson MG, et al. Long term Trends in the incidence
and Survival; with Heart Failure. N Engl J Med. 2002;347:1397-1402.
5.
Hoobs FDR, Davis RC, Roalfe AK, et al. Reliability of N-Terminal ProBrain Natriuretic Peptide Assay in Diagnosis of Heart Failure: Cohort Study
in Representative and High Risk Community Population. BMJ.
2002;324:1498-1502.
6.
The European Society of Cardiology. ESC Guidelines for the Diagnosis and
Treatment of Acute and Chronic Heart Failure 2012. European Heart
Journal. 2012;33:1787-1847.
7.
Mukoyama M, Nakao K, Saito Y, et al. Increase Human Brain Natriuretic
Peptide in Congestive Heart Failure. N Engl J Med. 1990;323:757-758.
8.
The Task Force for the Diagnosis and Treatment of Chronic Heart Failure.
European Society of Cardiology. Guidelines for the Diagnosis and Treatment
of Chronic Heart Failure. European Heart J. 2001;22:1527-1560.
9.
Hartmann F, Packer M, Coats AJ, et al. Prognostic Impact of Plasma NTerminal Pro-Brain Natriuretic Peptide in Severe Chronic Congestive Heart
Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative
Survival (COPERNICUS) Trial. Circulation. 2004;110:1780-1786.
10. Fonarow GC, Peacock WF, Phillips CO, et al. Admission B-Type Natriuretic
Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart
Failure. J Am Coll Cardiol. 2007;49:1943–1950
11. Van Kimmenade RR, Januzzi JL. Red cell distribution width measurement:
what role does it have in heart failure?. Rev Esp Cardiol. 2012;65(7):593594
12. Felker GM, Allen LA, Pocock SJ, et al. Red cell distribution width as a
novel prognostic marker in heart failure: data from the CHARM Program
and the Duke Databank. J Am Coll Cardiol. 2007;50:40–47.
13. Jackson CE, Dalzell JR, Bezlyak V, et al. Red cell distribution width has
incremental prognostic value to B-type natriuretic peptide in acute heart
failure. Eur J Heart Fail. 2009;11:1152–1154.
30
Universitas Sumatera Utara
14. Al-Najjar Y, Goode KM, Zhang J, Cleland JG, Clark AL. Red cell
distribution width: an inexpensive and powerful prognostic marker in heart
failure. Eur J Heart Fail. 2009;11:1155–1162.
15. Constantino BT. The red cell histogram and the dimorphic red cell
population. Labmedicine. 2011;42:300-308
16. Turgeon ML. Clinical hematology theory and procedures. Fifth edition.
Philadelphia: Lippincott Williams & Wilkins, a Wolters Kluwer Business.
2012;103-104,543-544
17. Ciesla B. Hematology in practice. Philadelphia: FA Davis Company.
2007;22-26
18. Hammarsten O, Jacobsson S, Fu M. Red cell distribution width in chronic
heart failure: a new independent marker for prognosis?. Eur J Heart Fail.
2010;12:213-214
19. Marks PW. Anemia: clinical approach. Dalam: Schmaier AH, Lazarus HM,
penyunting. Concise guide to hamatology. Oxford: Wiley-blackwell.
2012;30
20. Suryaatmadja, M. Perkembangan Terkini B-type Natriuretic Peptide (BNP)
Petanda Biokimia Gagal Jantung. Dalam: Suryaatmadja, M. (ed.) Pendidikan
Berkesinambungan Patologi Klinik. 2004. Jakarta: Departemen Patologi
Klinik FK UI. 2004:157-171.
21. de Lemos JA, McGuire D.K, Drazner M.H. B-Type Natriuretic Peptide in
Cardiovascular Disease. The Lancet. 2003;362:316-322.
22. Hall C. Essential Biochemistry and Physiology of (NT-pro) BNP. Eur J
Heart Fail. 2004;6:257-260
23. Kragelund C, Grønning B, Kober L, Hildebrandt P, Steffensen R. NTerminal pro-B-Type Natriuretic Peptide and Long-Term Mortality in Stable
Coronary Heart Disease. N Engl J Med. 2005;352(7): 666-675
24. Clerico A, Emdin M. Diagnostic Accuracy and Prognostic Relevance of the
Measurement of Cardiac Natriuretic Peptides: a Review. Clinical Chemistry.
2004;50:33-50.
25. Apple FS, Panteghini M, Ravkilde J, et al. Quality Specifications for B-type
Natriuretic Peptide Assays. Clinical Chemistry. 2005;51:486-493.
26. Talwar S, Squire I.B, Downie P.F, Davies J.E, Ng L.L. Plasma N terminal
Pro-Brain Natriuretic Peptide and Cardiotrophin 1 are Raised in Unstable
Angina. Heart 2000;84:421–424.
27. Choi EY, Kwon HM, Yoon YW, Kim D, Kim HS. Assessment of Extent of
Myocardial Ischemia in Patients with Non-ST Elevation Acute Coronary
Syndrome Using Serum B-Type Natriuretic Peptide Level. Yonsei Med J.
2004;45(2):255-262.
28. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Nielsen B.
Increased Cardiac BNP Expression Associated with Myocardial Ischemia.
FASEB J. 2003;17:1105-1107.
31
Universitas Sumatera Utara
29. Anwaruddin S, Llyod-Jones DM, Baggish A, et al. Renal function,
Congestive Heart Failure and Aminoterminal pro-brain Natriuretic Peptide
Measurement: Results from the ProBNP Investigation of Dyspnea in the
Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47:91-97
30. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and
renal function in the diagnosis of heart failure: an analysis from the
Breathing Not Properly Multinational Study. Am J Kidney Dis.
2003;41(3):571-579.
31. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med.
1998;339(5):321-328.
32. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnand R, et al.
Clinical application of B-type natriuretic peptide (BNP) testing. Eur J Heart
Fail. 2003;24(19):1710–1718.
33. Douglas, P.S. The Left Atrium. A Biomarker of Chronic Diastolic
Dysfunction and Cardiovascular Disease Risk. J Am Coll Cardiol.
2003;42:1206-1207.
34. Jackson G, Gibbs CR, Davies MK, Lip GYH. ABC of Heart Failure:
Pathophysiology. BMJ. 2000;320:167-170.
35. Bonaque JC, Pascual-Figal DA, Manzano-Fernández S, et al. El ancho de
distribución eritrocitaria aporta valor pronóstico adicional en pacientes
ambulatorios con insuficiencia cardiac crónica. Rev Esp Cardiol.
2012;65:606–612.
36. Van Kimmenade RRJ, Mohammed AA, Uthamalingam S, et al. Red blood
cell distribution width and one-year mortality in acute heart failure. Eur J
Heart Fail. 2010;12:129–136.
37. Förhécz Z, Gombos T, Borgulya G, Pozsonyi Z, Prohászka Z, Jánoskuti L.
Red cell distribution width in heart failure: prediction of clinical events and
relationship with markers of ineffective erythropoiesis, inflammation, renal
function, and nutritional state. Am Heart J. 2009;158:659–666.
38. Allen LA, Felker GM, Mehra MR, et al. Validation and potential
mechanisms of red cell distribution width as a prognostic marker in heart
failure. J Card Fail. 2010;16:230–238.
39. O’Brien TX. Iron metabolisme, anemia, and heart failure. J Am Coll Cardiol.
2011; 58:1252-1253.
40. Okonko DO, Mandal AKJ, Missouris CG, Poole-Wilson PA. Disordered
iron homeostasis in chronic heart failure: prevalence, predictors, and
relations to anemia, exercise capacity, and survival. J Am Coll Cardiol.
2011;58:1241–1251.
41. Pemberton CJ, Yandle TG, Rademaker MT, Charles CJ, Aitken GD, Espiner
EA. Amino-terminal proBNP in ovine plasma: evidence for enhanced
secretion in response to cardiac overload. American Journal of Physiology Heart and Circulatory Physiology. 1998;275:1200-1208.
32
Universitas Sumatera Utara
42. Januzzi JL, Kimmenade RV, Lainchbury J, et.al. NT-proBNP Testing for
Diagnosis of Short-term Prognosis in Acute Destabilized Heart Failure: an
International Pooled Analysis of 1256 Patient. European Heart Journal.
2006;27:330-337.
43. Hebl V, Zakhrova MY, Canoniero M, Duprez D, Garcia S. Correlation of
Natriuretic Peptides and Inferior Vena Cava Size in Patient with Congestion
Heart Failure. Vascular Health Risk Management. 2012;8:213-218.
44. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-Terminal Pro-Brain
Natriuretic Peptide and Adrenomedullin: New Neurohormonal Predictors of
Left Ventricular Function and Prognosis after Myocardial Infarction.
Circulation. 1998;97:1921-1929.
45. de Derus S, Pharand C, Williamson DR. Brain Natriuretic Peptide in the
Management of Heart Failure. The Versatile Neurohormone. Chest.
2004;125:652-668.
46. Celic A, Kok F, Kadi H. Relationship between red cell distribution width
and echocardiographic parameters in patients with diastolic heart failure.
Kaohsiung Journal of Medical Sciences. 2012;28:165-172.
47. Patel KV, Ferrucci L, Ershler BW, Longo DL, Guralnik JM. Red Cell
Distribution Width and the Risk of Death in Middle-aged and Older Adults.
Arch Intern Med. 2009;169(5):515-523.
48. Sastroasmoro Sudigdo, Ismael Sofyan. Dasar-dasar Metodologi Penelitian
Klinis. Edisi ke-2. Jakarta: Sagung Seto. 2002;280.
33
Universitas Sumatera Utara
1.
Francis GS, Gassler JP, Sonnenblick EH. Pathophysiology and Diagnosis of
Heart Failure. In: Fusler V, Alexander RW, O’Rourke RA (ed). The Heart
10th edition. 2005;1:655-685.
2.
Colucci WS. Nesiritide for the treatment of decompensated heart failure. J
Card Fail. 2001;7(1):92-100.
3.
Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated
into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of
Heart Failure in Adults A Report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines
Developed in Collaboration With the International Society for Heart and
Lung Transplantation. J Am Coll Cardiol. 2009;119:393-475.
4.
Levy D, Kenchaiah, Larson MG, et al. Long term Trends in the incidence
and Survival; with Heart Failure. N Engl J Med. 2002;347:1397-1402.
5.
Hoobs FDR, Davis RC, Roalfe AK, et al. Reliability of N-Terminal ProBrain Natriuretic Peptide Assay in Diagnosis of Heart Failure: Cohort Study
in Representative and High Risk Community Population. BMJ.
2002;324:1498-1502.
6.
The European Society of Cardiology. ESC Guidelines for the Diagnosis and
Treatment of Acute and Chronic Heart Failure 2012. European Heart
Journal. 2012;33:1787-1847.
7.
Mukoyama M, Nakao K, Saito Y, et al. Increase Human Brain Natriuretic
Peptide in Congestive Heart Failure. N Engl J Med. 1990;323:757-758.
8.
The Task Force for the Diagnosis and Treatment of Chronic Heart Failure.
European Society of Cardiology. Guidelines for the Diagnosis and Treatment
of Chronic Heart Failure. European Heart J. 2001;22:1527-1560.
9.
Hartmann F, Packer M, Coats AJ, et al. Prognostic Impact of Plasma NTerminal Pro-Brain Natriuretic Peptide in Severe Chronic Congestive Heart
Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative
Survival (COPERNICUS) Trial. Circulation. 2004;110:1780-1786.
10. Fonarow GC, Peacock WF, Phillips CO, et al. Admission B-Type Natriuretic
Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart
Failure. J Am Coll Cardiol. 2007;49:1943–1950
11. Van Kimmenade RR, Januzzi JL. Red cell distribution width measurement:
what role does it have in heart failure?. Rev Esp Cardiol. 2012;65(7):593594
12. Felker GM, Allen LA, Pocock SJ, et al. Red cell distribution width as a
novel prognostic marker in heart failure: data from the CHARM Program
and the Duke Databank. J Am Coll Cardiol. 2007;50:40–47.
13. Jackson CE, Dalzell JR, Bezlyak V, et al. Red cell distribution width has
incremental prognostic value to B-type natriuretic peptide in acute heart
failure. Eur J Heart Fail. 2009;11:1152–1154.
30
Universitas Sumatera Utara
14. Al-Najjar Y, Goode KM, Zhang J, Cleland JG, Clark AL. Red cell
distribution width: an inexpensive and powerful prognostic marker in heart
failure. Eur J Heart Fail. 2009;11:1155–1162.
15. Constantino BT. The red cell histogram and the dimorphic red cell
population. Labmedicine. 2011;42:300-308
16. Turgeon ML. Clinical hematology theory and procedures. Fifth edition.
Philadelphia: Lippincott Williams & Wilkins, a Wolters Kluwer Business.
2012;103-104,543-544
17. Ciesla B. Hematology in practice. Philadelphia: FA Davis Company.
2007;22-26
18. Hammarsten O, Jacobsson S, Fu M. Red cell distribution width in chronic
heart failure: a new independent marker for prognosis?. Eur J Heart Fail.
2010;12:213-214
19. Marks PW. Anemia: clinical approach. Dalam: Schmaier AH, Lazarus HM,
penyunting. Concise guide to hamatology. Oxford: Wiley-blackwell.
2012;30
20. Suryaatmadja, M. Perkembangan Terkini B-type Natriuretic Peptide (BNP)
Petanda Biokimia Gagal Jantung. Dalam: Suryaatmadja, M. (ed.) Pendidikan
Berkesinambungan Patologi Klinik. 2004. Jakarta: Departemen Patologi
Klinik FK UI. 2004:157-171.
21. de Lemos JA, McGuire D.K, Drazner M.H. B-Type Natriuretic Peptide in
Cardiovascular Disease. The Lancet. 2003;362:316-322.
22. Hall C. Essential Biochemistry and Physiology of (NT-pro) BNP. Eur J
Heart Fail. 2004;6:257-260
23. Kragelund C, Grønning B, Kober L, Hildebrandt P, Steffensen R. NTerminal pro-B-Type Natriuretic Peptide and Long-Term Mortality in Stable
Coronary Heart Disease. N Engl J Med. 2005;352(7): 666-675
24. Clerico A, Emdin M. Diagnostic Accuracy and Prognostic Relevance of the
Measurement of Cardiac Natriuretic Peptides: a Review. Clinical Chemistry.
2004;50:33-50.
25. Apple FS, Panteghini M, Ravkilde J, et al. Quality Specifications for B-type
Natriuretic Peptide Assays. Clinical Chemistry. 2005;51:486-493.
26. Talwar S, Squire I.B, Downie P.F, Davies J.E, Ng L.L. Plasma N terminal
Pro-Brain Natriuretic Peptide and Cardiotrophin 1 are Raised in Unstable
Angina. Heart 2000;84:421–424.
27. Choi EY, Kwon HM, Yoon YW, Kim D, Kim HS. Assessment of Extent of
Myocardial Ischemia in Patients with Non-ST Elevation Acute Coronary
Syndrome Using Serum B-Type Natriuretic Peptide Level. Yonsei Med J.
2004;45(2):255-262.
28. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Nielsen B.
Increased Cardiac BNP Expression Associated with Myocardial Ischemia.
FASEB J. 2003;17:1105-1107.
31
Universitas Sumatera Utara
29. Anwaruddin S, Llyod-Jones DM, Baggish A, et al. Renal function,
Congestive Heart Failure and Aminoterminal pro-brain Natriuretic Peptide
Measurement: Results from the ProBNP Investigation of Dyspnea in the
Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47:91-97
30. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and
renal function in the diagnosis of heart failure: an analysis from the
Breathing Not Properly Multinational Study. Am J Kidney Dis.
2003;41(3):571-579.
31. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med.
1998;339(5):321-328.
32. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnand R, et al.
Clinical application of B-type natriuretic peptide (BNP) testing. Eur J Heart
Fail. 2003;24(19):1710–1718.
33. Douglas, P.S. The Left Atrium. A Biomarker of Chronic Diastolic
Dysfunction and Cardiovascular Disease Risk. J Am Coll Cardiol.
2003;42:1206-1207.
34. Jackson G, Gibbs CR, Davies MK, Lip GYH. ABC of Heart Failure:
Pathophysiology. BMJ. 2000;320:167-170.
35. Bonaque JC, Pascual-Figal DA, Manzano-Fernández S, et al. El ancho de
distribución eritrocitaria aporta valor pronóstico adicional en pacientes
ambulatorios con insuficiencia cardiac crónica. Rev Esp Cardiol.
2012;65:606–612.
36. Van Kimmenade RRJ, Mohammed AA, Uthamalingam S, et al. Red blood
cell distribution width and one-year mortality in acute heart failure. Eur J
Heart Fail. 2010;12:129–136.
37. Förhécz Z, Gombos T, Borgulya G, Pozsonyi Z, Prohászka Z, Jánoskuti L.
Red cell distribution width in heart failure: prediction of clinical events and
relationship with markers of ineffective erythropoiesis, inflammation, renal
function, and nutritional state. Am Heart J. 2009;158:659–666.
38. Allen LA, Felker GM, Mehra MR, et al. Validation and potential
mechanisms of red cell distribution width as a prognostic marker in heart
failure. J Card Fail. 2010;16:230–238.
39. O’Brien TX. Iron metabolisme, anemia, and heart failure. J Am Coll Cardiol.
2011; 58:1252-1253.
40. Okonko DO, Mandal AKJ, Missouris CG, Poole-Wilson PA. Disordered
iron homeostasis in chronic heart failure: prevalence, predictors, and
relations to anemia, exercise capacity, and survival. J Am Coll Cardiol.
2011;58:1241–1251.
41. Pemberton CJ, Yandle TG, Rademaker MT, Charles CJ, Aitken GD, Espiner
EA. Amino-terminal proBNP in ovine plasma: evidence for enhanced
secretion in response to cardiac overload. American Journal of Physiology Heart and Circulatory Physiology. 1998;275:1200-1208.
32
Universitas Sumatera Utara
42. Januzzi JL, Kimmenade RV, Lainchbury J, et.al. NT-proBNP Testing for
Diagnosis of Short-term Prognosis in Acute Destabilized Heart Failure: an
International Pooled Analysis of 1256 Patient. European Heart Journal.
2006;27:330-337.
43. Hebl V, Zakhrova MY, Canoniero M, Duprez D, Garcia S. Correlation of
Natriuretic Peptides and Inferior Vena Cava Size in Patient with Congestion
Heart Failure. Vascular Health Risk Management. 2012;8:213-218.
44. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-Terminal Pro-Brain
Natriuretic Peptide and Adrenomedullin: New Neurohormonal Predictors of
Left Ventricular Function and Prognosis after Myocardial Infarction.
Circulation. 1998;97:1921-1929.
45. de Derus S, Pharand C, Williamson DR. Brain Natriuretic Peptide in the
Management of Heart Failure. The Versatile Neurohormone. Chest.
2004;125:652-668.
46. Celic A, Kok F, Kadi H. Relationship between red cell distribution width
and echocardiographic parameters in patients with diastolic heart failure.
Kaohsiung Journal of Medical Sciences. 2012;28:165-172.
47. Patel KV, Ferrucci L, Ershler BW, Longo DL, Guralnik JM. Red Cell
Distribution Width and the Risk of Death in Middle-aged and Older Adults.
Arch Intern Med. 2009;169(5):515-523.
48. Sastroasmoro Sudigdo, Ismael Sofyan. Dasar-dasar Metodologi Penelitian
Klinis. Edisi ke-2. Jakarta: Sagung Seto. 2002;280.
33
Universitas Sumatera Utara